Ask an Expert

Question of the Day

Bryan Roth, M.D., Ph.D.
September 16, 2011

There are several novel medications in both early- and later-stage clinical development which hold out hope for new treatment options as well as many in earlier stages of the pipeline. If only one of these proved effective (for example Gly-T I inhibitors currently in Phase III trials), we could expect new options within a couple of years. The early stage medications, coming mainly from pharmaceutical companies, are at least 5 years away. A new pan-NIH-initiative to accelerate drug discovery via academic labs could yield fruit, with a fair amount of luck, within the 5-year timeline.

Bryan L. Roth, M.D., Ph.D.
Scientific Council Member
Michael Hooker Distinguished Professor
Director, NIMH Psychoactive Drug Screening Program
University of North Carolina Chapel Hill Medical School

Bryan Roth, M.D., Ph.D.
Q Is there a link between vitamin D3 deficiency and schizophrenia?
A There are several studies which have suggested some link between both high... More >
Robert C. Malenka, M.D., Ph.D. - Brain & behavior research expert on depression
Q Your work is fascinating. It is frightening to think about neurotransmitters in the brain being manipulated to reduce or eliminate depressed behaviors. How do you foresee these malfunctions in brain circuitry and synaptic connections being treated?
A The hope of all neuroscience researchers is that by defining the... More >